MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Researchers from NTU and MIT developed COMET, an AI model that predicts optimal lipid nanoparticle formulations for RNA medicine delivery, published in Nature Nanotechnology.

MIT researchers used generative AI to design two novel antibiotics capable of killing drug-resistant gonorrhea and MRSA in laboratory and animal tests.

Daré Bioscience received a $6 million non-dilutive grant installment, bringing total funding to $37.8 million of up to $49 million committed for DARE-LARC1 contraceptive development.

MIT engineers have developed an implantable device that automatically administers glucagon to prevent life-threatening hypoglycemic episodes in diabetics, with testing in mice showing blood sugar stabilization within 10 minutes.

Scientists at the University of Nottingham have developed a cryogenic mass spectrometry approach that reveals the precise structure and molecular orientation within lipid nanoparticles used in RNA therapeutics.

Artis BioSolutions has emerged from stealth mode with the strategic acquisition of Landmark Bio, positioning itself as a premier CDMO for advanced genetic medicine development.

Bayer will present pivotal Phase III data for gadoquatrane, its investigational low-dose contrast agent for MRI, demonstrating comparable efficacy to standard macrocyclic agents at 60% lower gadolinium dose.

STEMCELL Technologies, Canada's largest biotechnology company, acquired substantially all assets of SQZ Biotechnologies for $400+ million, gaining access to mechanoporation technology and over 400 patents for cell therapy delivery applications.

Elicio Therapeutics' ELI-002 vaccine demonstrated robust immune responses in 84% of patients with pancreatic and colorectal cancer, showing a 56-fold increase in antitumor T cells.

MIT researchers have developed a quarter-sized implantable device that generates oxygen to sustain insulin-producing islet cells, potentially eliminating the need for daily insulin injections in type 1 diabetes patients.